This article is more than 5 years old. Information may no longer be current.
Phase 1 trial initiated for first-in-class ATPase modulator for IBD
Click Here to Manage Email Alerts
A phase 1 clinical trial of LYC-30937, a novel, orally administered, gut-directed ATPase modulator being studied for the treatment of inflammatory bowel disease, has commenced, according to a press release from the manufacturer.
LYC-30937 (Lycera Corp.) selectively induces apoptosis in disease-causing immune cells while sparing normal cells, according to the release.
“Inflammatory bowel diseases including ulcerative colitis and Crohn’s disease, are chronic, life-long autoimmune diseases with significant medical needs and the potential for life-threatening complications,” H. Jeffrey Wilkins, MD, chief medical officer of Lycera, said in the release. “In contrast to current injectable treatments, LYC-30937 is an oral agent that acts on a novel target, locally in the gut. Our development plan looks to demonstrate whether the promising preclinical data translates into an effective and well-tolerated novel treatment for patients with ulcerative colitis and inflammatory bowel disease.”
The trial will involve a cohort of healthy volunteers, and is expected to be completed by the end of 2015, the release said.
“The initiation of a clinical program for LYC-30937 marks a major milestone for Lycera,” Paul Sekhri, president and CEO of Lycera Corp., said in the release. “This is our first program to enter the clinic, as well as the first ATPase modulator to commence clinical testing. Lycera is dedicated to advancing a portfolio of drugs based on breakthrough science that have the potential to offer substantial advances for patient treatment. We are proud of the progress of our lead program, and look forward to further accelerating additional candidates in our pipeline.”
Disclosures: Wilkins and Sekhri are employees of Lycera Corp.